112 related articles for article (PubMed ID: 34717193)
21. Anti-PD-1 checkpoint blockade improves the efficacy of a melphalan-based therapy in experimental melanoma.
Kiffin R; Johansson J; Olofsson Bagge R; Martner A
Eur J Surg Oncol; 2021 Sep; 47(9):2460-2464. PubMed ID: 33980416
[TBL] [Abstract][Full Text] [Related]
22. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
Niknam S; Barsoumian HB; Schoenhals JE; Jackson HL; Yanamandra N; Caetano MS; Li A; Younes AI; Cadena A; Cushman TR; Chang JY; Nguyen QN; Gomez DR; Diab A; Heymach JV; Hwu P; Cortez MA; Welsh JW
Clin Cancer Res; 2018 Nov; 24(22):5735-5743. PubMed ID: 29784675
[No Abstract] [Full Text] [Related]
23. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma.
Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L
Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264
[TBL] [Abstract][Full Text] [Related]
24. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
Redmond WL; Linch SN; Kasiewicz MJ
Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
[TBL] [Abstract][Full Text] [Related]
25. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
Colombo MP
Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
[TBL] [Abstract][Full Text] [Related]
26. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
27. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
29. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
[TBL] [Abstract][Full Text] [Related]
30. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
[TBL] [Abstract][Full Text] [Related]
31. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
[TBL] [Abstract][Full Text] [Related]
32. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
33. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
Zhu X; Lang J
J Gynecol Oncol; 2017 Sep; 28(5):e64. PubMed ID: 28657225
[TBL] [Abstract][Full Text] [Related]
34. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy.
Houot R; Levy R
Blood; 2009 Apr; 113(15):3546-52. PubMed ID: 18941113
[TBL] [Abstract][Full Text] [Related]
35. Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth.
Badeaux MD; Rolig AS; Agnello G; Enzler D; Kasiewicz MJ; Priddy L; Wiggins JF; Muir A; Sullivan MR; Van Cleef J; Daige C; Vander Heiden MG; Rajamanickam V; Wooldridge JE; Redmond WL; Rowlinson SW
Cancer Immunol Res; 2021 Apr; 9(4):415-429. PubMed ID: 33500272
[TBL] [Abstract][Full Text] [Related]
36. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
37. Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.
Nawaf MG; Ulvmar MH; Withers DR; McConnell FM; Gaspal FM; Webb GJ; Jones ND; Yagita H; Allison JP; Lane PJL
J Immunol; 2017 Aug; 199(3):974-981. PubMed ID: 28646041
[TBL] [Abstract][Full Text] [Related]
38. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.
Speranza MC; Passaro C; Ricklefs F; Kasai K; Klein SR; Nakashima H; Kaufmann JK; Ahmed AK; Nowicki MO; Obi P; Bronisz A; Aguilar-Cordova E; Aguilar LK; Guzik BW; Breakefield X; Weissleder R; Freeman GJ; Reardon DA; Wen PY; Chiocca EA; Lawler SE
Neuro Oncol; 2018 Jan; 20(2):225-235. PubMed ID: 29016938
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
[TBL] [Abstract][Full Text] [Related]
40. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
